{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:21:34Z","timestamp":1790914894907,"version":"4.1.0"},"reference-count":169,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40265-025-02275-w","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T13:19:34Z","timestamp":1768310374000},"page":"177-202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Lipid-Lowering Therapies in Patients with Chronic Kidney Disease: A Perspective on High-Density Lipoprotein Cholesterol"],"prefix":"10.1007","volume":"86","author":[{"given":"Mohammad Abdullah Al Zubair","family":"Naim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Sumida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elani","family":"Streja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fridtjof","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Lowell","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamyar","family":"Kalantar-Zadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8204-911X","authenticated-orcid":false,"given":"Csaba P.","family":"Kovesdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,13]]},"reference":[{"issue":"7","key":"2275_CR1","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41581-024-00820-6","volume":"20","author":"A Francis","year":"2024","unstructured":"Francis A, Harhay MN, Ong ACM, Tummalapalli SL, Ortiz A, Fogo AB, et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024;20(7):473\u201385. https:\/\/doi.org\/10.1038\/s41581-024-00820-6.","journal-title":"Nat Rev Nephrol"},{"key":"2275_CR2","unstructured":"Prevention CfDCa. Chronic Kidney Disease in the United States, 2023. 2024. Available from: https:\/\/www.cdc.gov\/kidney-disease\/php\/data-research\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/kidneydisease\/publications-resources\/ckd-national-facts.html. Accessed 6 Jun 2025."},{"issue":"8","key":"2275_CR3","doi-asserted-by":"publisher","first-page":"e93","DOI":"10.1161\/CIR.0000000000001123","volume":"147","author":"CW Tsao","year":"2023","unstructured":"Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, et al. Heart disease and stroke statistics\u20142023 update: a report from the American Heart Association. Circulation. 2023;147(8):e93\u2013621. https:\/\/doi.org\/10.1161\/CIR.0000000000001123.","journal-title":"Circulation"},{"issue":"9731","key":"2275_CR4","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/s0140-6736(10)60674-5","volume":"375","author":"K Matsushita","year":"2010","unstructured":"Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073\u201381. https:\/\/doi.org\/10.1016\/s0140-6736(10)60674-5.","journal-title":"Lancet"},{"issue":"7","key":"2275_CR5","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/S2213-8587(15)00040-6","volume":"3","author":"K Matsushita","year":"2015","unstructured":"Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol. 2015;3(7):514\u201325. https:\/\/doi.org\/10.1016\/S2213-8587(15)00040-6.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"2275_CR6","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.numecd.2021.09.037","volume":"32","author":"C Lee","year":"2022","unstructured":"Lee C, Park JT, Chang T-I, Kang EW, Nam KH, Joo YS, et al. Low-density lipoprotein cholesterol levels and adverse clinical outcomes in chronic kidney disease: results from the KNOW-CKD. Nutr Metab Cardiovasc Dis. 2022;32(2):410\u20139. https:\/\/doi.org\/10.1016\/j.numecd.2021.09.037.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"2275_CR7","doi-asserted-by":"publisher","first-page":"1037618","DOI":"10.3389\/fnut.2022.1037618","volume":"9","author":"SH Suh","year":"2022","unstructured":"Suh SH, Oh TR, Choi HS, Kim CS, Bae EH, Oh KH, et al. Serum triglycerides level is independently associated with renal outcomes in patients with non-dialysis chronic kidney disease: results from KNOW-CKD study. Front Nutr. 2022;9:1037618. https:\/\/doi.org\/10.3389\/fnut.2022.1037618.","journal-title":"Front Nutr"},{"key":"2275_CR8","doi-asserted-by":"publisher","unstructured":"Kochanek KD, Murphy SL, Xu J, and Arias E, Mortality in the United States, 2022, in NCHS Data Brief, no 492. 2024, National Center for Health Statistics: Hyattsville, MD. https:\/\/doi.org\/10.15620\/cdc:135850.","DOI":"10.15620\/cdc:135850"},{"key":"2275_CR9","volume-title":"Lippincott\u2019s illustrated reviews: biochemistry fifth edition","author":"RAF Harvey","year":"2011","unstructured":"Harvey RAF, Denise R. Chapter 18: cholesterol and steroid metabolism. In: Harvey RA, editor. Lippincott\u2019s illustrated reviews: biochemistry fifth edition. 5th ed. Philadelphia: Wolters Kluwer Health\/Lippincott Williams & Wilkins; 2011.","edition":"5"},{"issue":"4","key":"2275_CR10","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nrneph.2012.33","volume":"8","author":"M Epstein","year":"2012","unstructured":"Epstein M, Vaziri ND. Statins in the management of dyslipidemia associated with chronic kidney disease. Nat Rev Nephrol. 2012;8(4):214\u201323. https:\/\/doi.org\/10.1038\/nrneph.2012.33.","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"2275_CR11","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/nrneph.2010.36","volume":"6","author":"ND Vaziri","year":"2010","unstructured":"Vaziri ND, Navab M, Fogelman AM. HDL metabolism and activity in chronic kidney disease. Nat Rev Nephrol. 2010;6(5):287\u201396. https:\/\/doi.org\/10.1038\/nrneph.2010.36.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"2275_CR12","doi-asserted-by":"publisher","first-page":"F262","DOI":"10.1152\/ajprenal.00099.2005","volume":"290","author":"ND Vaziri","year":"2006","unstructured":"Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol. 2006;290(2):F262\u201372. https:\/\/doi.org\/10.1152\/ajprenal.00099.2005.","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"2275_CR13","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1111\/joim.20027","volume":"296","author":"I Gruber","year":"2024","unstructured":"Gruber I, Kollerits B, Forer L, Di Maio S, Schachtl-Riess JF, Kheirkhah A, et al. Lipoprotein(a) concentrations and cardiovascular disease in patients with chronic kidney disease: results from the German Chronic Kidney Disease study. J Intern Med. 2024;296(6):510\u201326. https:\/\/doi.org\/10.1111\/joim.20027.","journal-title":"J Intern Med"},{"issue":"6","key":"2275_CR14","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1007\/s40620-023-01590-3","volume":"36","author":"L Barbagelata","year":"2023","unstructured":"Barbagelata L, Masson W, Corral P, Lavalle-Cobo A, Nogueira JP, Rosa Diez G. Relationship between lipoprotein(a) levels, cardiovascular outcomes and death in patients with chronic kidney disease: a systematic review of prospective studies. J Nephrol. 2023;36(6):1549\u201359. https:\/\/doi.org\/10.1007\/s40620-023-01590-3.","journal-title":"J Nephrol"},{"issue":"3","key":"2275_CR15","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1046\/j.1523-1755.2003.00803.x","volume":"63","author":"K Kalantar-Zadeh","year":"2003","unstructured":"Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63(3):793\u2013808. https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00803.x.","journal-title":"Kidney Int"},{"key":"2275_CR16","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/1471-2369-14-132","volume":"14","author":"A Kuznik","year":"2013","unstructured":"Kuznik A, Mardekian J, Tarasenko L. Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001\u20132010. BMC Nephrol. 2013;14:132. https:\/\/doi.org\/10.1186\/1471-2369-14-132.","journal-title":"BMC Nephrol"},{"key":"2275_CR17","unstructured":"National Heart L, and Blood Institute. Framingham Heart Study (FHS). 2023. Available from: https:\/\/www.nhlbi.nih.gov\/science\/framingham-heart-study-fhs. Accessed 14 June 2025."},{"issue":"5","key":"2275_CR18","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","volume":"62","author":"T Gordon","year":"1977","unstructured":"Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977;62(5):707\u201314. https:\/\/doi.org\/10.1016\/0002-9343(77)90874-9.","journal-title":"Am J Med"},{"issue":"6","key":"2275_CR19","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1161\/01.atv.8.6.737","volume":"8","author":"PWF Wilson","year":"1988","unstructured":"Wilson PWF, Castelli WP. High density lipoprotein cholesterol and mortality- the Framingham Heart Study. Atherosclerosis. 1988;8(6):737\u201341. https:\/\/doi.org\/10.1161\/01.atv.8.6.737.","journal-title":"Atherosclerosis"},{"issue":"13","key":"2275_CR20","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJMoa064278","volume":"357","author":"P Barter","year":"2007","unstructured":"Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med. 2007;357(13):1301\u201310. https:\/\/doi.org\/10.1056\/NEJMoa064278.","journal-title":"N Engl J Med"},{"issue":"6","key":"2275_CR21","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.011162","volume":"8","author":"KH Nam","year":"2019","unstructured":"Nam KH, Chang TI, Joo YS, Kim J, Lee S, Lee C, et al. Association between serum high-density lipoprotein cholesterol levels and progression of chronic kidney disease: results from the KNOW-CKD. J Am Heart Assoc. 2019;8(6):e011162. https:\/\/doi.org\/10.1161\/JAHA.118.011162.","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"2275_CR22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1007\/s001250050694","volume":"40","author":"H Yokoyama","year":"1997","unstructured":"Yokoyama H, Tomonaga O, Hirayama M, Ishii A, Takeda M, Babazono T, et al. Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients. Diabetologia. 1997;40(4):405\u201311. https:\/\/doi.org\/10.1007\/s001250050694.","journal-title":"Diabetologia"},{"issue":"9","key":"2275_CR23","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1001\/archinte.158.9.998","volume":"158","author":"M Ravid","year":"1998","unstructured":"Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med. 1998;158(9):998\u20131004. https:\/\/doi.org\/10.1001\/archinte.158.9.998.","journal-title":"Arch Intern Med"},{"issue":"5","key":"2275_CR24","doi-asserted-by":"publisher","first-page":"743","DOI":"10.2337\/diacare.22.5.743","volume":"22","author":"R Klein","year":"1999","unstructured":"Klein R, Klein BE, Moss SE, Cruickshanks KJ, Brazy PC. The 10-year incidence of renal insufficiency in people with type 1 diabetes. Diabetes Care. 1999;22(5):743\u201351. https:\/\/doi.org\/10.2337\/diacare.22.5.743.","journal-title":"Diabetes Care"},{"issue":"8","key":"2275_CR25","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1681\/asn.V1482084","volume":"14","author":"ES Schaeffner","year":"2003","unstructured":"Schaeffner ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol. 2003;14(8):2084\u201391. https:\/\/doi.org\/10.1681\/asn.V1482084.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"2275_CR26","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/ki.1997.260","volume":"51","author":"LG Hunsicker","year":"1997","unstructured":"Hunsicker LG, Adler S, Caggiula A, England BK, Greene T, et al. Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study. Kidney Int. 1997;51(6):1908\u201319. https:\/\/doi.org\/10.1038\/ki.1997.260.","journal-title":"Kidney Int"},{"issue":"1","key":"2275_CR27","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1681\/asn.2006060674","volume":"18","author":"CP Kovesdy","year":"2007","unstructured":"Kovesdy CP, Anderson JE, Kalantar-Zadeh K. Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome. J Am Soc Nephrol. 2007;18(1):304\u201311. https:\/\/doi.org\/10.1681\/asn.2006060674.","journal-title":"J Am Soc Nephrol"},{"key":"2275_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8120549","author":"AB M\u00e1rquez","year":"2020","unstructured":"M\u00e1rquez AB, Nazir S, van der Vorst EPC. High-density lipoprotein modifications: a pathological consequence or cause of disease progression? Biomedicines. 2020. https:\/\/doi.org\/10.3390\/biomedicines8120549.","journal-title":"Biomedicines"},{"issue":"5","key":"2275_CR29","doi-asserted-by":"publisher","first-page":"612","DOI":"10.4093\/dmj.2023.0067","volume":"47","author":"SH Suh","year":"2023","unstructured":"Suh SH, Kim SW. Dyslipidemia in patients with chronic kidney disease: an updated overview. Diabetes Metab J. 2023;47(5):612\u201329. https:\/\/doi.org\/10.4093\/dmj.2023.0067.","journal-title":"Diabetes Metab J"},{"issue":"1","key":"2275_CR30","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1186\/s12882-024-03808-3","volume":"25","author":"Z Xu","year":"2024","unstructured":"Xu Z, Yang S, Cui L. Understanding the heterogeneity and dysfunction of HDL in chronic kidney disease: insights from recent reviews. BMC Nephrol. 2024;25(1):400. https:\/\/doi.org\/10.1186\/s12882-024-03808-3.","journal-title":"BMC Nephrol"},{"issue":"2","key":"2275_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.trsl.2008.11.007","volume":"153","author":"H Moradi","year":"2009","unstructured":"Moradi H, Pahl MV, Elahimehr R, Vaziri ND. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res. 2009;153(2):77\u201385. https:\/\/doi.org\/10.1016\/j.trsl.2008.11.007.","journal-title":"Transl Res"},{"issue":"4","key":"2275_CR32","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1159\/000186303","volume":"57","author":"PO Attman","year":"1991","unstructured":"Attman PO, Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia\u2013relation to renal function and dialysis. Nephron. 1991;57(4):401\u201310. https:\/\/doi.org\/10.1159\/000186303.","journal-title":"Nephron"},{"issue":"6","key":"2275_CR33","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/ndt\/14.6.1462","volume":"14","author":"ND Vaziri","year":"1999","unstructured":"Vaziri ND, Deng G, Liang K. Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant. 1999;14(6):1462\u20136. https:\/\/doi.org\/10.1093\/ndt\/14.6.1462.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"2275_CR34","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1046\/j.1523-1755.2001.00734.x","volume":"59","author":"ND Vaziri","year":"2001","unstructured":"Vaziri ND, Liang K, Parks JS. Down-regulation of hepatic lecithin:cholesterol acyltransferase gene expression in chronic renal failure. Kidney Int. 2001;59(6):2192\u20136. https:\/\/doi.org\/10.1046\/j.1523-1755.2001.00734.x.","journal-title":"Kidney Int"},{"issue":"1","key":"2275_CR35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1053\/ajkd.2001.25196","volume":"38","author":"H Kimura","year":"2001","unstructured":"Kimura H, Miyazaki R, Suzuki S, Gejyo F, Yoshida H. Cholesteryl ester transfer protein as a protective factor against vascular disease in hemodialysis patients. Am J Kidney Dis. 2001;38(1):70\u20136. https:\/\/doi.org\/10.1053\/ajkd.2001.25196.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2275_CR36","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1097\/mnh.0000000000000217","volume":"25","author":"H Yang","year":"2016","unstructured":"Yang H, Fogo AB, Kon V. Kidneys: key modulators of high-density lipoprotein levels and function. Curr Opin Nephrol Hypertens. 2016;25(3):174\u20139. https:\/\/doi.org\/10.1097\/mnh.0000000000000217.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"6","key":"2275_CR37","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0027-9684(15)30368-0","volume":"103","author":"ND Vaziri","year":"2011","unstructured":"Vaziri ND, Navab K, Gollapudi P, Moradi H, Pahl MV, Barton CH, et al. Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease. J Natl Med Assoc. 2011;103(6):524\u201333. https:\/\/doi.org\/10.1016\/S0027-9684(15)30368-0.","journal-title":"J Natl Med Assoc"},{"issue":"2","key":"2275_CR38","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1046\/j.1523-1755.1999.00585.x","volume":"56","author":"K Liang","year":"1999","unstructured":"Liang K, Vaziri ND. Down-regulation of hepatic high-density lipoprotein receptor, SR-B1, in nephrotic syndrome. Kidney Int. 1999;56(2):621\u20136. https:\/\/doi.org\/10.1046\/j.1523-1755.1999.00585.x.","journal-title":"Kidney Int"},{"issue":"1","key":"2275_CR39","doi-asserted-by":"publisher","first-page":"81","DOI":"10.5551\/jat.30015","volume":"23","author":"H Honda","year":"2016","unstructured":"Honda H, Hirano T, Ueda M, Kojima S, Mashiba S, Hayase Y, et al. High-density lipoprotein subfractions and their oxidized subfraction particles in patients with chronic kidney disease. J Atheroscler Thromb. 2016;23(1):81\u201394. https:\/\/doi.org\/10.5551\/jat.30015.","journal-title":"J Atheroscler Thromb"},{"issue":"5","key":"2275_CR40","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1681\/asn.2011070668","volume":"23","author":"T Weichhart","year":"2012","unstructured":"Weichhart T, Kopecky C, Kubicek M, Haidinger M, D\u00f6ller D, Katholnig K, et al. Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol. 2012;23(5):934\u201347. https:\/\/doi.org\/10.1681\/asn.2011070668.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"2275_CR41","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1681\/asn.2013111219","volume":"26","author":"C Kopecky","year":"2015","unstructured":"Kopecky C, Haidinger M, Birner-Gr\u00fcnberger R, Darnhofer B, Kaltenecker CC, Marsche G, et al. Restoration of renal function does not correct impairment of uremic HDL properties. J Am Soc Nephrol. 2015;26(3):565\u201375. https:\/\/doi.org\/10.1681\/asn.2013111219.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"2275_CR42","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrneph.2015.180","volume":"12","author":"ND Vaziri","year":"2016","unstructured":"Vaziri ND. HDL abnormalities in nephrotic syndrome and chronic kidney disease. Nat Rev Nephrol. 2016;12(1):37\u201347. https:\/\/doi.org\/10.1038\/nrneph.2015.180.","journal-title":"Nat Rev Nephrol"},{"issue":"25","key":"2275_CR43","doi-asserted-by":"publisher","first-page":"e1046","DOI":"10.1161\/CIR.0000000000000624","volume":"139","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1046\u201381. https:\/\/doi.org\/10.1161\/CIR.0000000000000624.","journal-title":"Circulation"},{"issue":"8","key":"2275_CR44","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1161\/01.ATV.12.8.911","volume":"12","author":"RP Mensink","year":"1992","unstructured":"Mensink RP, Katan MB. Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials. Arterioscler Thromb Vasc Biol. 1992;12(8):911\u20139. https:\/\/doi.org\/10.1161\/01.ATV.12.8.911.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"2275_CR45","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1161\/CIRCULATIONAHA.112.000443","volume":"128","author":"AV Khera","year":"2013","unstructured":"Khera AV, Plutzky J. Management of low levels of high-density lipoprotein-cholesterol. Circulation. 2013;128(1):72\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.112.000443.","journal-title":"Circulation"},{"issue":"6 Suppl","key":"2275_CR46","doi-asserted-by":"publisher","first-page":"S502","DOI":"10.1097\/00005768-200106001-00021","volume":"33","author":"AS Leon","year":"2001","unstructured":"Leon AS, Sanchez OA. Response of blood lipids to exercise training alone or combined with dietary intervention. Med Sci Sports Exerc. 2001;33(6 Suppl):S502\u201315. https:\/\/doi.org\/10.1097\/00005768-200106001-00021.","journal-title":"Med Sci Sports Exerc"},{"issue":"2","key":"2275_CR47","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1093\/ajcn\/56.2.320","volume":"56","author":"AM Dattilo","year":"1992","unstructured":"Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. Am J Clin Nutr. 1992;56(2):320\u20138. https:\/\/doi.org\/10.1093\/ajcn\/56.2.320.","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"2275_CR48","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/s0091-7435(03)00110-5","volume":"37","author":"K Maeda","year":"2003","unstructured":"Maeda K, Noguchi Y, Fukui T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. Prev Med. 2003;37(4):283\u201390. https:\/\/doi.org\/10.1016\/s0091-7435(03)00110-5.","journal-title":"Prev Med"},{"issue":"7","key":"2275_CR49","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1056\/NEJM199108153250703","volume":"325","author":"PD Wood","year":"1991","unstructured":"Wood PD, Stefanick ML, Williams PT, Haskell WL. The effects on plasma lipoproteins of a prudent weight-reducing diet, with or without exercise, in overweight men and women. N Engl J Med. 1991;325(7):461\u20136.","journal-title":"N Engl J Med"},{"issue":"10","key":"2275_CR50","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.metabol.2006.05.014","volume":"55","author":"KA Varady","year":"2006","unstructured":"Varady KA, Lamarche B, Santosa S, Demonty I, Charest A, Jones PJ. Effect of weight loss resulting from a combined low-fat diet\/exercise regimen on low-density lipoprotein particle size and distribution in obese women. Metabolism. 2006;55(10):1302\u20137.","journal-title":"Metabolism"},{"key":"2275_CR51","unstructured":"Health FOoWs. Cholesterol Medicines Guide. 2022. Available from: https:\/\/www.fda.gov\/consumers\/womens-health-topics\/cholesterol-medicines-guide. Accessed 11 June 2025."},{"issue":"4","key":"2275_CR52","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10557-008-6113-z","volume":"22","author":"F McTaggart","year":"2008","unstructured":"McTaggart F, Jones P. Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit. Cardiovasc Drugs Ther. 2008;22(4):321\u201338. https:\/\/doi.org\/10.1007\/s10557-008-6113-z.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"2275_CR53","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1177\/2047487313483600","volume":"20","author":"H Naci","year":"2013","unstructured":"Naci H, Brugts JJ, Fleurence R, Ades AE. Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials. Eur J Prev Cardiol. 2013;20(4):658\u201370. https:\/\/doi.org\/10.1177\/2047487313483600.","journal-title":"Eur J Prev Cardiol"},{"issue":"5","key":"2275_CR54","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/j.1365-2125.2003.02060.x","volume":"57","author":"BM Cheung","year":"2004","unstructured":"Cheung BM, Lauder IJ, Lau CP, Kumana CR. Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol. 2004;57(5):640\u201351. https:\/\/doi.org\/10.1111\/j.1365-2125.2003.02060.x.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"2275_CR55","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1080\/08998280.2003.11927928","volume":"16","author":"J Patel","year":"2003","unstructured":"Patel J, Sheehan V, Gurk-Turner EC. Ezetimibe (Zetia): a new type of lipid-lowering agent. Proc (Bayl Univ Med Cent). 2003;16(3):354\u20138. https:\/\/doi.org\/10.1080\/08998280.2003.11927928.","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"3","key":"2275_CR56","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41569-018-0107-8","volume":"16","author":"MS Sabatine","year":"2019","unstructured":"Sabatine MS. PCSK9 inhibitors: clinical evidence and implementation. Nat Rev Cardiol. 2019;16(3):155\u201365. https:\/\/doi.org\/10.1038\/s41569-018-0107-8.","journal-title":"Nat Rev Cardiol"},{"issue":"16","key":"2275_CR57","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1001\/archinte.159.16.1893","volume":"159","author":"MH Davidson","year":"1999","unstructured":"Davidson MH, Dillon MA, Gordon B, Jones P, Samuels J, Weiss S, et al. Colesevelam hydrochloride (Cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med. 1999;159(16):1893\u2013900. https:\/\/doi.org\/10.1001\/archinte.159.16.1893.","journal-title":"Arch Intern Med"},{"issue":"1","key":"2275_CR58","doi-asserted-by":"publisher","first-page":"8729003","DOI":"10.1155\/2022\/8729003","volume":"2022","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Suo Y, Yang L, Zhang X, Yu Q, Zeng M, et al. Effect of PCSK9 inhibitor on blood lipid levels in patients with high and very-high CVD risk: a systematic review and meta-analysis. Cardiol Res Pract. 2022;2022(1):8729003. https:\/\/doi.org\/10.1155\/2022\/8729003.","journal-title":"Cardiol Res Pract"},{"issue":"10","key":"2275_CR59","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/S0002-9149(02)02798-4","volume":"90","author":"CA Dujovne","year":"2002","unstructured":"Dujovne CA, Ettinger MP, McNeer JF, Lipka LJ, LeBeaut AP, Suresh R, et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am J Cardiol. 2002;90(10):1092\u20137. https:\/\/doi.org\/10.1016\/S0002-9149(02)02798-4.","journal-title":"Am J Cardiol"},{"key":"2275_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1269172","author":"F Omidi","year":"2023","unstructured":"Omidi F, Rahmannia M, Shahidi Bonjar AH, Mohammadsharifi P, Nasiri MJ, Sarmastzadeh T. Ezetimibe and atherosclerotic cardiovascular disease: a systematic review and meta-analysis. Front Cardiovasc Med. 2023. https:\/\/doi.org\/10.3389\/fcvm.2023.1269172.","journal-title":"Front Cardiovasc Med"},{"issue":"4","key":"2275_CR61","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1161\/CIRCGENETICS.114.000952","volume":"8","author":"S Ross","year":"2015","unstructured":"Ross S, D\u2019Mello M, Anand SS, Eikelboom J, Consortium* CAD, Stewart AFR, et al. Effect of bile acid sequestrants on the risk of cardiovascular events. Circ Cardiovasc Genet. 2015;8(4):618\u201327. https:\/\/doi.org\/10.1161\/CIRCGENETICS.114.000952.","journal-title":"Circ Cardiovasc Genet"},{"issue":"1","key":"2275_CR62","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/1074248417724868","volume":"23","author":"TD Filippatos","year":"2018","unstructured":"Filippatos TD, Kei A, Rizos CV, Elisaf MS. Effects of PCSK9 inhibitors on other than low-density lipoprotein cholesterol lipid variables. J Cardiovasc Pharmacol Ther. 2018;23(1):3\u201312. https:\/\/doi.org\/10.1177\/1074248417724868.","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"4","key":"2275_CR63","doi-asserted-by":"publisher","first-page":"194","DOI":"10.13105\/wjma.v2.i4.194","volume":"2","author":"SLY Zheng","year":"2014","unstructured":"Zheng SLY, Han TT, Zhang Y, Jiang DD, Hu YM. Systematic review and meta-analysis of statins-fibrates therapy in diabetic dyslipidemia patients. World J Meta-Anal. 2014;2(4):194\u2013203. https:\/\/doi.org\/10.13105\/wjma.v2.i4.194.","journal-title":"World J Meta-Anal"},{"issue":"19","key":"2275_CR64","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1161\/01.cir.98.19.2088","volume":"98","author":"B Staels","year":"1998","unstructured":"Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98(19):2088\u201393. https:\/\/doi.org\/10.1161\/01.cir.98.19.2088.","journal-title":"Circulation"},{"issue":"3","key":"2275_CR65","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/MOL.0b013e3283613a68","volume":"24","author":"VS Kamanna","year":"2013","unstructured":"Kamanna VS, Ganji SH, Kashyap ML. Recent advances in niacin and lipid metabolism. Curr Opin Lipidol. 2013;24(3):239\u201345. https:\/\/doi.org\/10.1097\/MOL.0b013e3283613a68.","journal-title":"Curr Opin Lipidol"},{"issue":"4","key":"2275_CR66","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.2224","volume":"2","author":"E D'Andrea","year":"2019","unstructured":"D\u2019Andrea E, Hey SP, Ramirez CL, Kesselheim AS. Assessment of the role of niacin in managing cardiovascular disease outcomes: a systematic review and meta-analysis. JAMA Netw Open. 2019;2(4):e192224. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.2224.","journal-title":"JAMA Netw Open"},{"issue":"8","key":"2275_CR67","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1194\/jlr.M700108-JLR200","volume":"48","author":"CC van der Hoogt","year":"2007","unstructured":"van der Hoogt CC, de Haan W, Westerterp M, Hoekstra M, Dallinga-Thie GM, Romijn JA, et al. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J Lipid Res. 2007;48(8):1763\u201371. https:\/\/doi.org\/10.1194\/jlr.M700108-JLR200.","journal-title":"J Lipid Res"},{"issue":"2","key":"2275_CR68","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","volume":"45","author":"RS Birjmohun","year":"2005","unstructured":"Birjmohun RS, Hutten BA, Kastelein JJP, Stroes ESG. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005;45(2):185\u201397. https:\/\/doi.org\/10.1016\/j.jacc.2004.10.031.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2275_CR69","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1161\/hq1001.096624","volume":"21","author":"T Sakai","year":"2001","unstructured":"Sakai T, Kamanna VS, Kashyap ML. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol. Arterioscler Thromb Vasc Biol. 2001;21(11):1783\u20139. https:\/\/doi.org\/10.1161\/hq1001.096624.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2275_CR70","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2025.02.303","author":"MAAZ Naim","year":"2025","unstructured":"Naim MAAZ, Thomas F, Streja E, Davis RL, Kalantar-Zadeh K, Sumida K, et al. Effect of different classes of lipid-lowering therapy on HDL cholesterol level in patients with non-dialysis-dependent CKD. Am J Kidney Dis. 2025. https:\/\/doi.org\/10.1053\/j.ajkd.2025.02.303.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"2275_CR71","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2215\/cjn.05440517","volume":"13","author":"R Malhotra","year":"2018","unstructured":"Malhotra R, Katz R, Hoofnagle A, Bostom A, Rifkin DE, McBride R, et al. The effect of extended release niacin on markers of mineral metabolism in CKD. Clin J Am Soc Nephrol. 2018;13(1):36\u201344. https:\/\/doi.org\/10.2215\/cjn.05440517.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"2275_CR72","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1681\/asn.2008040349","volume":"20","author":"KL Adeney","year":"2009","unstructured":"Adeney KL, Siscovick DS, Ix JH, Seliger SL, Shlipak MG, Jenny NS, et al. Association of serum phosphate with vascular and valvular calcification in moderate CKD. J Am Soc Nephrol. 2009;20(2):381\u20137. https:\/\/doi.org\/10.1681\/asn.2008040349.","journal-title":"J Am Soc Nephrol"},{"issue":"9729","key":"2275_CR73","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1016\/s0140-6736(10)60656-3","volume":"375","author":"M Jun","year":"2010","unstructured":"Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375(9729):1875\u201384. https:\/\/doi.org\/10.1016\/s0140-6736(10)60656-3.","journal-title":"Lancet"},{"issue":"4","key":"2275_CR74","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jacc.2012.10.030","volume":"61","author":"PM Lavigne","year":"2013","unstructured":"Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol. 2013;61(4):440\u20136. https:\/\/doi.org\/10.1016\/j.jacc.2012.10.030.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2275_CR75","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1161\/01.CIR.100.6.594","volume":"100","author":"M Eriksson","year":"1999","unstructured":"Eriksson M, Carlson LA, Miettinen TA, Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Circulation. 1999;100(6):594\u20138. https:\/\/doi.org\/10.1161\/01.CIR.100.6.594.","journal-title":"Circulation"},{"issue":"10","key":"2275_CR76","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/S0022-2275(20)32212-4","volume":"42","author":"MN Nanjee","year":"2001","unstructured":"Nanjee MN, Cooke CJ, Garvin R, Semeria F, Lewis G, Olszewski WL, et al. Intravenous apoA-I\/lecithin discs increase pre-\u03b2-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res. 2001;42(10):1586\u201393. https:\/\/doi.org\/10.1016\/S0022-2275(20)32212-4.","journal-title":"J Lipid Res"},{"issue":"15","key":"2275_CR77","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1001\/jama.297.15.jpc70004","volume":"297","author":"J-C Tardif","year":"2007","unstructured":"Tardif J-C, Gr\u00e9goire J, L\u2019Allier PL, Ibrahim R, Lesp\u00e9rance J, Heinonen TM, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosisA randomized controlled trial. JAMA. 2007;297(15):1675\u201382. https:\/\/doi.org\/10.1001\/jama.297.15.jpc70004.","journal-title":"JAMA"},{"issue":"9","key":"2275_CR78","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1001\/jamacardio.2018.2121","volume":"3","author":"SJ Nicholls","year":"2018","unstructured":"Nicholls SJ, Andrews J, Kastelein JJP, Merkely B, Nissen SE, Ray KK, et al. Effect of serial infusions of CER-001, a pre-\u03b2 high-density lipoprotein mimetic, on coronary atherosclerosis in patients following acute coronary syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: a randomized clinical trial. JAMA Cardiol. 2018;3(9):815\u201322. https:\/\/doi.org\/10.1001\/jamacardio.2018.2121.","journal-title":"JAMA Cardiol"},{"issue":"17","key":"2275_CR79","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","volume":"290","author":"SE Nissen","year":"2003","unstructured":"Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290(17):2292\u2013300. https:\/\/doi.org\/10.1001\/jama.290.17.2292.","journal-title":"JAMA"},{"key":"2275_CR80","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.ahj.2018.11.008","volume":"208","author":"CM Gibson","year":"2019","unstructured":"Gibson CM, Kerneis M, Yee MK, Daaboul Y, Korjian S, Mehr AP, et al. The CSL112-2001 trial: safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction. Am Heart J. 2019;208:81\u201390. https:\/\/doi.org\/10.1016\/j.ahj.2018.11.008.","journal-title":"Am Heart J"},{"issue":"22","key":"2275_CR81","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.jacc.2024.03.396","volume":"83","author":"TJ Povsic","year":"2024","unstructured":"Povsic TJ, Korjian S, Bahit MC, Chi G, Duffy D, Alexander JH, et al. Effect of reconstituted human apolipoprotein A-I on recurrent ischemic events in survivors of acute MI. JACC. 2024;83(22):2163\u201374. https:\/\/doi.org\/10.1016\/j.jacc.2024.03.396.","journal-title":"JACC"},{"issue":"11","key":"2275_CR82","doi-asserted-by":"publisher","first-page":"2302","DOI":"10.1194\/jlr.M800075-JLR200","volume":"49","author":"BJ Van Lenten","year":"2008","unstructured":"Van Lenten BJ, Wagner AC, Jung C-L, Ruchala P, Waring AJ, Lehrer RI, et al. Anti-inflammatory apoA-I-mimetic peptides bind oxidized lipids with much higher affinity than human apoA-I *. J Lipid Res. 2008;49(11):2302\u201311. https:\/\/doi.org\/10.1194\/jlr.M800075-JLR200.","journal-title":"J Lipid Res"},{"issue":"6","key":"2275_CR83","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1194\/jlr.P800003-JLR200","volume":"49","author":"LT Bloedon","year":"2008","unstructured":"Bloedon LT, Dunbar R, Duffy D, Pinell-Salles P, Norris R, DeGroot BJ, et al. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients*. J Lipid Res. 2008;49(6):1344\u201352. https:\/\/doi.org\/10.1194\/jlr.P800003-JLR200.","journal-title":"J Lipid Res"},{"issue":"2","key":"2275_CR84","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1194\/jlr.M011098","volume":"52","author":"CE Watson","year":"2011","unstructured":"Watson CE, Weissbach N, Kjems L, Ayalasomayajula S, Zhang Y, Chang I, et al. Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function [S]. J Lipid Res. 2011;52(2):361\u201373. https:\/\/doi.org\/10.1194\/jlr.M011098.","journal-title":"J Lipid Res"},{"issue":"9","key":"2275_CR85","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/j.jacc.2010.11.015","volume":"57","author":"SJ Nicholls","year":"2011","unstructured":"Nicholls SJ, Gordon A, Johansson J, Wolski K, Ballantyne CM, Kastelein JJP, et al. Efficacy and safety of a novel oral inducer of apolipoprotein A-I synthesis in statin-treated patients with stable coronary artery disease. J Am Coll Cardiol. 2011;57(9):1111\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2010.11.015.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2275_CR86","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.5114\/aoms.2016.62906","volume":"12","author":"BA Di Bartolo","year":"2016","unstructured":"Di Bartolo BA, Scherer DJ, Nicholls SJ. Inducing apolipoprotein A-I synthesis to reduce cardiovascular risk: from ASSERT to SUSTAIN and beyond. Arch Med Sci. 2016;12(6):1302\u20137. https:\/\/doi.org\/10.5114\/aoms.2016.62906.","journal-title":"Arch Med Sci"},{"issue":"1","key":"2275_CR87","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40256-015-0146-z","volume":"16","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Wolski K, Ballantyne CM, Barter PJ, Brewer HB, et al. Effect of the BET protein inhibitor, RVX-208, on progression of coronary atherosclerosis: results of the phase 2b, randomized, double-blind, multicenter, ASSURE trial. Am J Cardiovasc Drugs. 2016;16(1):55\u201365. https:\/\/doi.org\/10.1007\/s40256-015-0146-z.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"2","key":"2275_CR88","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40256-017-0250-3","volume":"18","author":"SJ Nicholls","year":"2018","unstructured":"Nicholls SJ, Ray KK, Johansson JO, Gordon A, Sweeney M, Halliday C, et al. Selective BET protein inhibition with apabetalone and cardiovascular events: a pooled analysis of trials in patients with coronary artery disease. Am J Cardiovasc Drugs. 2018;18(2):109\u201315. https:\/\/doi.org\/10.1007\/s40256-017-0250-3.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"5","key":"2275_CR89","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1194\/jlr.M800622-JLR200","volume":"50","author":"FM Sacks","year":"2009","unstructured":"Sacks FM, Rudel LL, Conner A, Akeefe H, Kostner G, Baki T, et al. Selective delipidation of plasma HDL enhances reverse cholesterol transport in vivo. J Lipid Res. 2009;50(5):894\u2013907. https:\/\/doi.org\/10.1194\/jlr.M800622-JLR200.","journal-title":"J Lipid Res"},{"issue":"24","key":"2275_CR90","doi-asserted-by":"publisher","first-page":"2727","DOI":"10.1016\/j.jacc.2009.12.067","volume":"55","author":"R Waksman","year":"2010","unstructured":"Waksman R, Torguson R, Kent KM, Pichard AD, Suddath WO, Satler LF, et al. A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome. JACC. 2010;55(24):2727\u201335. https:\/\/doi.org\/10.1016\/j.jacc.2009.12.067.","journal-title":"JACC"},{"issue":"1","key":"2275_CR91","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.cell.2008.04.052","volume":"134","author":"SJ Bensinger","year":"2008","unstructured":"Bensinger SJ, Bradley MN, Joseph SB, Zelcer N, Janssen EM, Hausner MA, et al. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell. 2008;134(1):97\u2013111. https:\/\/doi.org\/10.1016\/j.cell.2008.04.052.","journal-title":"Cell"},{"issue":"2","key":"2275_CR92","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.cmet.2010.07.002","volume":"12","author":"G Lo Sasso","year":"2010","unstructured":"Lo Sasso G, Murzilli S, Salvatore L, D\u2019Errico I, Petruzzelli M, Conca P, et al. Intestinal specific LXR activation stimulates reverse cholesterol transport and protects from atherosclerosis. Cell Metab. 2010;12(2):187\u201393. https:\/\/doi.org\/10.1016\/j.cmet.2010.07.002.","journal-title":"Cell Metab"},{"issue":"6","key":"2275_CR93","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1177\/0091270009335768","volume":"49","author":"A Katz","year":"2009","unstructured":"Katz A, Udata C, Ott E, Hickey L, Burczynski ME, Burghart P, et al. Safety, pharmacokinetics, and pharmacodynamics of single doses of LXR-623, a novel liver X-receptor agonist, in healthy participants. J Clin Pharmacol. 2009;49(6):643\u20139. https:\/\/doi.org\/10.1177\/0091270009335768.","journal-title":"J Clin Pharmacol"},{"key":"2275_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175953","volume":"956","author":"X Hua","year":"2023","unstructured":"Hua X, Wei X. Liver X receptors: from pharmacology to nanoparticle-based drug delivery. Eur J Pharmacol. 2023;956:175953. https:\/\/doi.org\/10.1016\/j.ejphar.2023.175953.","journal-title":"Eur J Pharmacol"},{"issue":"12","key":"2275_CR95","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1161\/ATVBAHA.109.191320","volume":"29","author":"D Masson","year":"2009","unstructured":"Masson D, Koseki M, Ishibashi M, Larson CJ, Miller SG, King BD, et al. Increased HDL cholesterol and ApoA-I in humans and mice treated with a novel SR-BI inhibitor. Arterioscler Thromb Vasc Biol. 2009;29(12):2054\u201360. https:\/\/doi.org\/10.1161\/ATVBAHA.109.191320.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"2","key":"2275_CR96","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.amjmed.2011.08.025","volume":"125","author":"SN Friedland","year":"2012","unstructured":"Friedland SN, Leong A, Filion KB, Genest J, Lega IC, Mottillo S, et al. The cardiovascular effects of peroxisome proliferator-activated receptor agonists. Am J Med. 2012;125(2):126\u201333. https:\/\/doi.org\/10.1016\/j.amjmed.2011.08.025.","journal-title":"Am J Med"},{"issue":"9684","key":"2275_CR97","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/S0140-6736(09)60870-9","volume":"374","author":"RR Henry","year":"2009","unstructured":"Henry RR, Lincoff AM, Mudaliar S, Rabbia M, Chognot C, Herz M. Effect of the dual peroxisome proliferator-activated receptor-\u03b1\/\u03b3 agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging study. Lancet. 2009;374(9684):126\u201335. https:\/\/doi.org\/10.1016\/S0140-6736(09)60870-9.","journal-title":"Lancet"},{"issue":"15","key":"2275_CR98","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1001\/jama.2014.3321","volume":"311","author":"AM Lincoff","year":"2014","unstructured":"Lincoff AM, Tardif JC, Schwartz GG, Nicholls SJ, Ryd\u00e9n L, Neal B, et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA. 2014;311(15):1515\u201325. https:\/\/doi.org\/10.1001\/jama.2014.3321.","journal-title":"JAMA"},{"issue":"1","key":"2275_CR99","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1161\/CIRCRESAHA.117.311978","volume":"122","author":"AR Tall","year":"2018","unstructured":"Tall AR, Rader DJ. Trials and tribulations of CETP inhibitors. Circ Res. 2018;122(1):106\u201312. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311978.","journal-title":"Circ Res"},{"issue":"21","key":"2275_CR100","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJP, Komajda M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109\u201322. https:\/\/doi.org\/10.1056\/NEJMoa0706628.","journal-title":"N Engl J Med"},{"issue":"13","key":"2275_CR101","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1056\/NEJMoa070635","volume":"356","author":"SE Nissen","year":"2007","unstructured":"Nissen SE, Tardif J-C, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356(13):1304\u201316. https:\/\/doi.org\/10.1056\/NEJMoa070635.","journal-title":"N Engl J Med"},{"issue":"22","key":"2275_CR102","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","volume":"367","author":"GG Schwartz","year":"2012","unstructured":"Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089\u201399. https:\/\/doi.org\/10.1056\/NEJMoa1206797.","journal-title":"N Engl J Med"},{"issue":"25","key":"2275_CR103","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","volume":"363","author":"CP Cannon","year":"2010","unstructured":"Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, Gotto AM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363(25):2406\u201315. https:\/\/doi.org\/10.1056\/NEJMoa1009744.","journal-title":"N Engl J Med"},{"issue":"20","key":"2275_CR104","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","volume":"376","author":"AM Lincoff","year":"2017","unstructured":"Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376(20):1933\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1609581.","journal-title":"N Engl J Med"},{"issue":"13","key":"2275_CR105","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","volume":"377","author":"Group THTRC","year":"2017","unstructured":"Group THTRC. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377(13):1217\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1706444.","journal-title":"N Engl J Med"},{"issue":"5","key":"2275_CR106","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/cpt.700","volume":"102","author":"R Krishna","year":"2017","unstructured":"Krishna R, Gheyas F, Liu Y, Hagen DR, Walker B, Chawla A, et al. Chronic administration of anacetrapib is associated with accumulation in adipose and slow elimination. Clin Pharmacol Ther. 2017;102(5):832\u201340. https:\/\/doi.org\/10.1002\/cpt.700.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"2275_CR107","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.70010","volume":"12","author":"SJ Nicholls","year":"2024","unstructured":"Nicholls SJ, Nelson AJ, Kastelein JJP, Ditmarsch M, Hsieh A, Johnson J, et al. Obicetrapib exhibits favorable physiochemical and pharmacokinetic properties compared to previous cholesteryl ester transfer protein inhibitors: an integrated summary of results from non-human primate studies and clinical trials. Pharmacol Res Perspect. 2024;12(6):e70010. https:\/\/doi.org\/10.1002\/prp2.70010.","journal-title":"Pharmacol Res Perspect"},{"issue":"6","key":"2275_CR108","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/clpt.2008.109","volume":"84","author":"R Krishna","year":"2008","unstructured":"Krishna R, Bergman A, Jin B, Fallon M, Cote J, Van Hoydonck P, et al. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin Pharmacol Ther. 2008;84(6):679\u201383. https:\/\/doi.org\/10.1038\/clpt.2008.109.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"2275_CR109","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/bcp.12380","volume":"78","author":"J Ford","year":"2014","unstructured":"Ford J, Lawson M, Fowler D, Maruyama N, Mito S, Tomiyasu K, et al. Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Br J Clin Pharmacol. 2014;78(3):498\u2013508. https:\/\/doi.org\/10.1111\/bcp.12380.","journal-title":"Br J Clin Pharmacol"},{"issue":"11","key":"2275_CR110","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1111\/jphp.12287","volume":"66","author":"JG Suico","year":"2014","unstructured":"Suico JG, Wang M-D, Friedrich S, Cannady EA, Konkoy CS, Ruotolo G, et al. Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults. J Pharm Pharmacol. 2014;66(11):1576\u201385. https:\/\/doi.org\/10.1111\/jphp.12287.","journal-title":"J Pharm Pharmacol"},{"issue":"14","key":"2275_CR111","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1093\/cvr\/cvab350","volume":"118","author":"NS Nurmohamed","year":"2021","unstructured":"Nurmohamed NS, Ditmarsch M, Kastelein JJP. Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents? Cardiovasc Res. 2021;118(14):2919\u201331. https:\/\/doi.org\/10.1093\/cvr\/cvab350.","journal-title":"Cardiovasc Res"},{"issue":"8","key":"2275_CR112","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","volume":"28","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls SJ, Ditmarsch M, Kastelein JJ, Rigby SP, Kling D, Curcio DL, et al. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med. 2022;28(8):1672\u20138. https:\/\/doi.org\/10.1038\/s41591-022-01936-7.","journal-title":"Nat Med"},{"issue":"9992","key":"2275_CR113","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S0140-6736(15)60158-1","volume":"386","author":"GK Hovingh","year":"2015","unstructured":"Hovingh GK, Kastelein JJP, van Deventer SJH, Round P, Ford J, Saleheen D, et al. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet. 2015;386(9992):452\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(15)60158-1.","journal-title":"Lancet"},{"issue":"10","key":"2275_CR114","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.5551\/jat.64828","volume":"31","author":"M Harada-Shiba","year":"2024","unstructured":"Harada-Shiba M, Davdison MH, Ditmarsch M, Hsieh A, Wuerdeman E, Kling D, et al. Obicetrapib as an adjunct to stable statin therapy in Japanese subjects: results from a randomized phase 2 trial. J Atheroscler Thromb. 2024;31(10):1386\u201397. https:\/\/doi.org\/10.5551\/jat.64828.","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"2275_CR115","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMoa2415820","volume":"393","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Nelson AJ, Ditmarsch M, Kastelein JJP, Ballantyne CM, Ray KK, et al. Safety and efficacy of obicetrapib in patients at high cardiovascular risk. N Engl J Med. 2025;393(1):51\u201361. https:\/\/doi.org\/10.1056\/NEJMoa2415820.","journal-title":"N Engl J Med"},{"key":"2275_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2025.08.002","author":"S Ahmad Wani","year":"2025","unstructured":"Ahmad Wani S, Naveed MA, Ali A, Saeed A, Azeem B, Ashraf S, et al. Updated meta-analysis of the lipid-lowering efficacy of Obicetrapib: a comprehensive review of randomized controlled trials. J Clin Lipidol. 2025. https:\/\/doi.org\/10.1016\/j.jacl.2025.08.002.","journal-title":"J Clin Lipidol"},{"issue":"14","key":"2275_CR117","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.jacc.2025.07.056","volume":"86","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Nelson AJ, Ray KK, Ballantyne CM, Ditmarsch M, Kling D, et al. Impact of obicetrapib on major adverse cardiovascular events in high-risk patients. JACC. 2025;86(14):1046\u201356. https:\/\/doi.org\/10.1016\/j.jacc.2025.07.056.","journal-title":"JACC"},{"issue":"4","key":"2275_CR118","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jacl.2023.05.098","volume":"17","author":"CM Ballantyne","year":"2023","unstructured":"Ballantyne CM, Ditmarsch M, Kastelein JJP, Nelson AJ, Kling D, Hsieh A, et al. Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: a randomized phase 2 trial. J Clin Lipidol. 2023;17(4):491\u2013503. https:\/\/doi.org\/10.1016\/j.jacl.2023.05.098.","journal-title":"J Clin Lipidol"},{"issue":"10491","key":"2275_CR119","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/S0140-6736(25)00721-4","volume":"405","author":"A Sarraju","year":"2025","unstructured":"Sarraju A, Brennan D, Hayden K, Stronczek A, Goldberg AC, Michos ED, et al. Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025;405(10491):1757\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(25)00721-4.","journal-title":"Lancet"},{"issue":"23","key":"2275_CR120","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1001\/jama.2018.7260","volume":"319","author":"A Kitchlu","year":"2018","unstructured":"Kitchlu A, Shapiro J, Amir E, Garg AX, Kim SJ, Wald R, et al. Representation of patients with chronic kidney disease in trials of cancer therapy. JAMA. 2018;319(23):2437\u20139. https:\/\/doi.org\/10.1001\/jama.2018.7260.","journal-title":"JAMA"},{"issue":"11","key":"2275_CR121","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1001\/jama.296.11.1377","volume":"296","author":"SG Coca","year":"2006","unstructured":"Coca SG, Krumholz HM, Garg AX, Parikh CR. Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease. JAMA. 2006;296(11):1377\u201384. https:\/\/doi.org\/10.1001\/jama.296.11.1377.","journal-title":"JAMA"},{"issue":"11","key":"2275_CR122","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1038\/sj.ki.5001934","volume":"70","author":"D Charytan","year":"2006","unstructured":"Charytan D, Kuntz RE. The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int. 2006;70(11):2021\u201330. https:\/\/doi.org\/10.1038\/sj.ki.5001934.","journal-title":"Kidney Int"},{"issue":"1","key":"2275_CR123","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.122.026551","volume":"12","author":"M Aeschbacher\u2010Germann","year":"2023","unstructured":"Aeschbacher\u2010Germann M, Kaiser N, Speierer A, Blum MR, Bauer DC, Del Giovane C, et al. Lipid\u2010lowering trials are not representative of patients managed in clinical practice: a systematic review and meta\u2010analysis of exclusion criteria. J Am Heart Assoc. 2023;12(1):e026551. https:\/\/doi.org\/10.1161\/JAHA.122.026551.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2275_CR124","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/kisup.2013.42","volume":"3","author":"KDIGO","year":"2013","unstructured":"KDIGO. KDIGO clinical practice guideline for lipid management in chronic kidney disease. Kidney Int Suppl. 2013;3(3):303\u20135. https:\/\/doi.org\/10.1038\/kisup.2013.42.","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"2275_CR125","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1056\/NEJMoa043545","volume":"353","author":"C Wanner","year":"2005","unstructured":"Wanner C, Krane V, M\u00e4rz W, Olschewski M, Mann JFE, Ruf G, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238\u201348. https:\/\/doi.org\/10.1056\/NEJMoa043545.","journal-title":"N Engl J Med"},{"issue":"14","key":"2275_CR126","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","volume":"360","author":"BC Fellstr\u00f6m","year":"2009","unstructured":"Fellstr\u00f6m BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360(14):1395\u2013407. https:\/\/doi.org\/10.1056\/NEJMoa0810177.","journal-title":"N Engl J Med"},{"issue":"9784","key":"2275_CR127","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181\u201392. https:\/\/doi.org\/10.1016\/S0140-6736(11)60739-3.","journal-title":"Lancet"},{"issue":"6","key":"2275_CR128","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2018.2311","volume":"1","author":"E Streja","year":"2018","unstructured":"Streja E, Gosmanova EO, Molnar MZ, Soohoo M, Moradi H, Potukuchi PK, et al. Association of continuation of statin therapy initiated before transition to chronic dialysis therapy with mortality after dialysis initiation. JAMA Netw Open. 2018;1(6):e182311. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.2311.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"2275_CR129","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006886","volume":"5","author":"Y-L Yan","year":"2015","unstructured":"Yan Y-L, Qiu B, Wang J, Deng S-B, Wu L, Jing X-D, et al. High-intensity statin therapy in patients with chronic kidney disease: a systematic review and meta-analysis. BMJ Open. 2015;5(5):e006886. https:\/\/doi.org\/10.1136\/bmjopen-2014-006886.","journal-title":"BMJ Open"},{"issue":"9326","key":"2275_CR130","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"Group HPSC","year":"2002","unstructured":"Group HPSC. MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial. Lancet. 2002;360(9326):7\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(02)09327-3.","journal-title":"Lancet"},{"issue":"2","key":"2275_CR131","doi-asserted-by":"publisher","first-page":"98","DOI":"10.7326\/0003-4819-138-2-200301210-00010","volume":"138","author":"M Tonelli","year":"2003","unstructured":"Tonelli M, Moy L, Sacks FM, Investigators ftCaRECT. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. Ann Intern Med. 2003;138(2):98\u2013104. https:\/\/doi.org\/10.7326\/0003-4819-138-2-200301210-00010.","journal-title":"Ann Intern Med"},{"issue":"22","key":"2275_CR132","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097\u2013107. https:\/\/doi.org\/10.1056\/NEJMoa1801174.","journal-title":"N Engl J Med"},{"issue":"12","key":"2275_CR133","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/s2213-8587(17)30313-3","volume":"5","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941\u201350. https:\/\/doi.org\/10.1016\/s2213-8587(17)30313-3.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2275_CR134","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.kint.2017.12.011","volume":"93","author":"PP Toth","year":"2018","unstructured":"Toth PP, Dwyer JP, Cannon CP, Colhoun HM, Rader DJ, Upadhyay A, et al. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease. Kidney Int. 2018;93(6):1397\u2013408. https:\/\/doi.org\/10.1016\/j.kint.2017.12.011.","journal-title":"Kidney Int"},{"issue":"23","key":"2275_CR135","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","volume":"73","author":"DM Charytan","year":"2019","unstructured":"Charytan DM, Sabatine MS, Pedersen TR, Im K, Park JG, Pineda AL, et al. Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial. J Am Coll Cardiol. 2019;73(23):2961\u201370. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.513.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2275_CR136","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019;380(1):11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1812792.","journal-title":"N Engl J Med"},{"issue":"22","key":"2275_CR137","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1161\/CIRCULATIONAHA.121.055560","volume":"144","author":"A Majithia","year":"2021","unstructured":"Majithia A, Bhatt DL, Friedman AN, Miller M, Steg PG, Brinton EA, et al. Benefits of icosapent ethyl across the range of kidney function in patients with established cardiovascular disease or diabetes: REDUCE-IT RENAL. Circulation. 2021;144(22):1750\u20139. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.055560.","journal-title":"Circulation"},{"issue":"3","key":"2275_CR138","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s40620-020-00707-2","volume":"33","author":"R Pontremoli","year":"2020","unstructured":"Pontremoli R, Bellizzi V, Bianchi S, Bigazzi R, Cernaro V, Del Vecchio L, et al. Management of dyslipidaemia in patients with chronic kidney disease: a position paper endorsed by the Italian Society of Nephrology. J Nephrol. 2020;33(3):417\u201330. https:\/\/doi.org\/10.1007\/s40620-020-00707-2.","journal-title":"J Nephrol"},{"issue":"6","key":"2275_CR139","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1053\/j.ajkd.2016.01.016","volume":"67","author":"X Su","year":"2016","unstructured":"Su X, Zhang L, Lv J, Wang J, Hou W, Xie X, et al. Effect of statins on kidney disease outcomes: a systematic review and meta-analysis. Am J Kidney Dis. 2016;67(6):881\u201392. https:\/\/doi.org\/10.1053\/j.ajkd.2016.01.016.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2275_CR140","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1159\/000189551","volume":"75","author":"O Samuelsson","year":"1997","unstructured":"Samuelsson O, Attman PO, Knight-Gibson C, Kron B, Larsson R, Mulec H, et al. Effect of gemfibrozil on lipoprotein abnormalities in chronic renal insufficiency: a controlled study in human chronic renal disease. Nephron. 1997;75(3):286\u201394. https:\/\/doi.org\/10.1159\/000189551.","journal-title":"Nephron"},{"issue":"5","key":"2275_CR141","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1053\/j.ajkd.2004.07.009","volume":"44","author":"M Tonelli","year":"2004","unstructured":"Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC. Effect of gemfibrozil on change in renal function in men with moderate chronic renal insufficiency and coronary disease. Am J Kidney Dis. 2004;44(5):832\u20139. https:\/\/doi.org\/10.1053\/j.ajkd.2004.07.009.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2275_CR142","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1053\/j.ajkd.2007.03.003","volume":"49","author":"G Dogra","year":"2007","unstructured":"Dogra G, Irish A, Chan D, Watts G. A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD. Am J Kidney Dis. 2007;49(6):776\u201385. https:\/\/doi.org\/10.1053\/j.ajkd.2007.03.003.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2275_CR143","first-page":"140","volume":"53","author":"A Levin","year":"2000","unstructured":"Levin A, Duncan L, Djurdjev O, Shapiro RJ, Frohlich J, Belanger A, et al. A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate. Clin Nephrol. 2000;53(2):140\u20136.","journal-title":"Clin Nephrol"},{"issue":"3","key":"2275_CR144","doi-asserted-by":"publisher","first-page":"354","DOI":"10.5301\/jn.5000011","volume":"25","author":"P Aramwit","year":"2012","unstructured":"Aramwit P, Srisawadwong R, Supasyndh O. Effectiveness and safety of extended-release nicotinic acid for reducing serum phosphorus in hemodialysis patients. J Nephrol. 2012;25(3):354\u201362. https:\/\/doi.org\/10.5301\/jn.5000011.","journal-title":"J Nephrol"},{"key":"2275_CR145","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04211007","author":"SC Cheng","year":"2008","unstructured":"Cheng SC, Young DO, Huang Y, Delmez JA, Coyne DW. A randomized, double-blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol. 2008. https:\/\/doi.org\/10.2215\/CJN.04211007.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2275_CR146","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4103\/0971-4065.98751","volume":"22","author":"M Edalat-Nejad","year":"2012","unstructured":"Edalat-Nejad M, Zameni F, Talaiei A. The effect of niacin on serum phosphorus levels in dialysis patients. Indian J Nephrol. 2012;22(3):174\u20138. https:\/\/doi.org\/10.4103\/0971-4065.98751.","journal-title":"Indian J Nephrol"},{"issue":"20","key":"2275_CR147","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1016\/j.jacc.2012.07.049","volume":"60","author":"M Jun","year":"2012","unstructured":"Jun M, Zhu B, Tonelli M, Jardine MJ, Patel A, Neal B, et al. Effects of fibrates in kidney disease: a systematic review and meta-analysis. J Am Coll Cardiol. 2012;60(20):2061\u201371. https:\/\/doi.org\/10.1016\/j.jacc.2012.07.049.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2275_CR148","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1111\/j.1523-1755.2004.00862.x","volume":"66","author":"M Tonelli","year":"2004","unstructured":"Tonelli M, Collins D, Robins S, Bloomfield H, Curhan GC. Gemfibrozil for secondary prevention of cardiovascular events in mild to moderate chronic renal insufficiency. Kidney Int. 2004;66(3):1123\u201330. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00862.x.","journal-title":"Kidney Int"},{"issue":"10","key":"2275_CR149","doi-asserted-by":"publisher","first-page":"4583","DOI":"10.1111\/dom.15815","volume":"26","author":"YY Hyun","year":"2024","unstructured":"Hyun YY, Kim K-S, Hong S, Han K, Park C-Y. Fenofibrate and risk of end-stage renal disease: A nationwide cohort study. Diabetes Obes Metab. 2024;26(10):4583\u201390. https:\/\/doi.org\/10.1111\/dom.15815.","journal-title":"Diabetes Obes Metab"},{"key":"2275_CR150","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030768","author":"A Hadjivasilis","year":"2022","unstructured":"Hadjivasilis A, Kouis P, Kousios A, Panayiotou A. The effect of fibrates on kidney function and chronic kidney disease progression: a systematic review and meta-analysis of randomised studies. J Clin Med. 2022. https:\/\/doi.org\/10.3390\/jcm11030768.","journal-title":"J Clin Med"},{"issue":"9500","key":"2275_CR151","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/s0140-6736(05)67667-2","volume":"366","author":"A Keech","year":"2005","unstructured":"Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849\u201361. https:\/\/doi.org\/10.1016\/s0140-6736(05)67667-2.","journal-title":"Lancet"},{"issue":"17","key":"2275_CR152","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","volume":"362","author":"HN Ginsberg","year":"2010","unstructured":"Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563\u201374. https:\/\/doi.org\/10.1056\/NEJMoa1001282.","journal-title":"N Engl J Med"},{"issue":"6","key":"2275_CR153","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/ki.2014.383","volume":"87","author":"RS Kalil","year":"2015","unstructured":"Kalil RS, Wang JH, de Boer IH, Mathew RO, Ix JH, Asif A, et al. Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post-hoc analysis of the AIM-HIGH trial. Kidney Int. 2015;87(6):1250\u20137. https:\/\/doi.org\/10.1038\/ki.2014.383.","journal-title":"Kidney Int"},{"key":"2275_CR154","doi-asserted-by":"publisher","DOI":"10.1159\/000543098","author":"R Takahashi","year":"2025","unstructured":"Takahashi R, Bui T-A, Elali I, Tran D, Sumida K, Thomas F, et al. The association of niacin use with kidney outcomes and mortality. Am J Nephrol. 2025. https:\/\/doi.org\/10.1159\/000543098.","journal-title":"Am J Nephrol"},{"issue":"7","key":"2275_CR155","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.7326\/L20-1300","volume":"174","author":"S Faguer","year":"2021","unstructured":"Faguer S, Colombat M, Chauveau D, Bernadet-Monrozies P, Beq A, Delas A, et al. Administration of the high-density lipoprotein mimetic CER-001 for inherited lecithin-cholesterol acyltransferase deficiency. Ann Intern Med. 2021;174(7):1022\u20135. https:\/\/doi.org\/10.7326\/L20-1300.","journal-title":"Ann Intern Med"},{"issue":"3","key":"2275_CR156","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/joim.13404","volume":"291","author":"C Pavanello","year":"2022","unstructured":"Pavanello C, Turri M, Strazzella A, Tulissi P, Pizzolitto S, De Maglio G, et al. The HDL mimetic CER-001 remodels plasma lipoproteins and reduces kidney lipid deposits in inherited lecithin:cholesterol acyltransferase deficiency. J Intern Med. 2022;291(3):364\u201370. https:\/\/doi.org\/10.1111\/joim.13404.","journal-title":"J Intern Med"},{"issue":"9","key":"2275_CR157","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.5551\/jat.RV22020","volume":"31","author":"Y Endo","year":"2024","unstructured":"Endo Y, Sasaki K, Ikewaki K. Bridging the gap between the bench and bedside: clinical applications of high-density lipoprotein function. J Atheroscler Thromb. 2024;31(9):1239\u201348. https:\/\/doi.org\/10.5551\/jat.RV22020.","journal-title":"J Atheroscler Thromb"},{"issue":"2","key":"2275_CR158","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3390\/ijms21020601","volume":"21","author":"J Rysz","year":"2020","unstructured":"Rysz J, Gluba-Brz\u00f3zka A, Rysz-G\u00f3rzy\u0144ska M, Franczyk B. The role and function of HDL in patients with chronic kidney disease and the risk of cardiovascular disease. Int J Mol Sci. 2020;21(2):601.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2275_CR159","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1038\/s41467-021-25703-3","volume":"12","author":"AF Schmidt","year":"2021","unstructured":"Schmidt AF, Hunt NB, Gordillo-Mara\u00f1\u00f3n M, Charoen P, Drenos F, Kivimaki M, et al. Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. Nat Commun. 2021;12(1):5640. https:\/\/doi.org\/10.1038\/s41467-021-25703-3.","journal-title":"Nat Commun"},{"issue":"4","key":"2275_CR160","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s40262-013-0035-z","volume":"52","author":"M Phelan","year":"2013","unstructured":"Phelan M, Anzures-Cabrera J, Carlile DJ, Rowell L, Kuhlmann O, Arold G, et al. Effect of hepatic and renal impairment on the pharmacokinetics of dalcetrapib: altered distribution of the active thiol? Clin Pharmacokinet. 2013;52(4):255\u201365. https:\/\/doi.org\/10.1007\/s40262-013-0035-z.","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"2275_CR161","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00228-016-2017-1","volume":"72","author":"DS Small","year":"2016","unstructured":"Small DS, Zhang W, Royalty J, Cannady EA, Downs D, Ortega D, et al. Effect of hepatic or renal impairment on the pharmacokinetics of evacetrapib. Eur J Clin Pharmacol. 2016;72(5):563\u201372. https:\/\/doi.org\/10.1007\/s00228-016-2017-1.","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"2275_CR162","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1002\/jcph.320","volume":"54","author":"B Lauring","year":"2014","unstructured":"Lauring B, Li XS, Liu Y, Corr C, Lazarus N, Cote J, et al. Influence of renal and hepatic impairment on the pharmacokinetics of anacetrapib. J Clin Pharmacol. 2014;54(11):1247\u201355. https:\/\/doi.org\/10.1002\/jcph.320.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"2275_CR163","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1002\/pds.4393","volume":"27","author":"D Talbot","year":"2018","unstructured":"Talbot D, Delaney JAC, Sandfort V, Herrington DM, McClelland RL. Importance of the lipid-related pathways in the association between statins, mortality, and cardiovascular disease risk: the Multi-Ethnic Study of Atherosclerosis. Pharmacoepidemiol Drug Saf. 2018;27(4):365\u201372. https:\/\/doi.org\/10.1002\/pds.4393.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"11","key":"2275_CR164","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.040464","volume":"14","author":"N Shah","year":"2025","unstructured":"Shah N, Lan Z, Brown CJ, Martin SS, Turchin A. Impact of statin nonacceptance on cardiovascular outcomes in patients with diabetes. J Am Heart Assoc. 2025;14(11):e040464. https:\/\/doi.org\/10.1161\/JAHA.124.040464.","journal-title":"J Am Heart Assoc"},{"key":"2275_CR165","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177443","volume":"998","author":"S Shi","year":"2025","unstructured":"Shi S, Zheng Z, Chen W, Song Y, Dou K. Low density lipoprotein cholesterol but not statins is the direct cause of intracerebral hemorrhage. Eur J Pharmacol. 2025;998:177443. https:\/\/doi.org\/10.1016\/j.ejphar.2025.177443.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"2275_CR166","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.artres.2017.10.015","volume":"20","author":"F Lamarche","year":"2017","unstructured":"Lamarche F, Agharazii M, Madore F, Goupil R. 1.1: Central blood pressure, statins and LDL-cholesterol: a mediation analysis. Artery Res. 2017;20(1):47\u201347. https:\/\/doi.org\/10.1016\/j.artres.2017.10.015.","journal-title":"Artery Res"},{"key":"2275_CR167","doi-asserted-by":"publisher","DOI":"10.1016\/j.xinn.2024.100713","author":"Z-M Chen","year":"2024","unstructured":"Chen Z-M, Mo J-L, Yang K-X, Jiang Y-Y, Wang C-J, Yang X, et al. Beyond low-density lipoprotein cholesterol levels: impact of prior statin treatment on ischemic stroke outcomes. Innovation. 2024. https:\/\/doi.org\/10.1016\/j.xinn.2024.100713.","journal-title":"Innovation"},{"issue":"9","key":"2275_CR168","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203702","volume":"13","author":"D Lee","year":"2018","unstructured":"Lee D, Joo HJ, Jung HW, Lim DS. Investigating potential mediator between statin and coronary artery calcification. PLoS ONE. 2018;13(9):e0203702. https:\/\/doi.org\/10.1371\/journal.pone.0203702.","journal-title":"PLoS ONE"},{"issue":"7","key":"2275_CR169","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.2337\/dc21-1977","volume":"45","author":"JP Ferreira","year":"2022","unstructured":"Ferreira JP, Vasques-N\u00f3voa F, Ferr\u00e3o D, Saraiva F, Falc\u00e3o-Pires I, Neves JS, et al. Fenofibrate and heart failure outcomes in patients with type 2 diabetes: analysis from ACCORD. Diabetes Care. 2022;45(7):1584\u201391. https:\/\/doi.org\/10.2337\/dc21-1977.","journal-title":"Diabetes Care"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02275-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-025-02275-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-025-02275-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T08:58:06Z","timestamp":1769849886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-025-02275-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,13]]},"references-count":169,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["2275"],"URL":"https:\/\/doi.org\/10.1007\/s40265-025-02275-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,13]]},"assertion":[{"value":"1 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest Disclosure"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MN and CK had the idea for the article; MN and CK performed the literature search and drafted the article; and KS, ES, FT, RD, and KK critically revised the work.\u00a0All authors have read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}